Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

RESEARCH TRIANGLE PARK, N.C., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation (NASDAQ: LQDA), today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news